Theranos, the digraced medical-technology startup that infamously inflated the capabilities of its devices, has secured $100 million in new funding in the form of a loan.
Theranos has come a long way from the days when it was a darling in the biotech industry. The Wall Street Journal‘s sources have claimed that the blood-testing firm has avoided bankruptcy by securing a $100 million loan from Fortress Investment Group. The move should keep Theranos afloat “through 2018,” founder Elizabeth Holmes reportedly said in an email. Naturally, though, there are strings attached — Fortress wants to see a return on its investment.